Authors’ Response to Letter to the Editor Regarding Comparative Efficacy of JAK Inhibitors for Moderate-to-Severe Rheumatoid Arthritis: A Network Meta-Analysis
Tóm tắt
Từ khóa
Tài liệu tham khảo
Stevenson M, Archer R, Tosh J, et al. Adalimumab, etanercept, infliximab, certolizumabpegol, golimumab, tocilizumab and abatacept for the treatment of rheumatoid arthritis not previously treated with disease-modifying antirheumatic drugs and after the failure of conventional disease-modifying antirheumatic drugs only: systematic review and economic evaluation. Health Technol Assess (Winchester, England). 2016;20(35):1–610.
Baricitinib for moderate to severe rheumatoid arthritis: Technology appraisal guidance. National Institute for Health Care and Excellence (NICE); 2017. Accessed 10 October 2020.
Upadacitinib for moderate to severe rheumatoid arthritis. National Institute for Health Care and Excellence (NICE); 2020. https://www.nice.org.uk/guidance/ta665. Accessed 10 Oct 2020.
Lee YH, Song GG. Relative efficacy and safety of tofacitinib, baricitinib, upadacitinib, and filgotinib in comparison to adalimumab in patients with active rheumatoid arthritis. Z Rheumatol. 2020;79:785–96. https://doi.org/10.1007/s00393-020-00750-1.
Fakhouri W, Wang X, de La Torre I, Nicolay C. A network meta-analysis to compare effectiveness of baricitinib and other treatments in rheumatoid arthritis patients with inadequate response to methotrexate. J Health Econ Outcomes Res. 2020;7(1):10–23.
Kremer JM, Schiff M, Muram D, Zhong J, Alam J, Genovese MC. Response to baricitinib therapy in patients with rheumatoid arthritis with inadequate response to csDMARDs as a function of baseline characteristics. RMD Open. 2018;4(1):e000581.
Kameda H, Takeuchi T, Yamaoka K, et al. Efficacy and safety of upadacitinib in Japanese patients with rheumatoid arthritis (SELECT-SUNRISE): a placebo-controlled phase IIb/III study. Rheumatology. 2020;59(11):3303–13.
Signorovitch JE, Betts KA, Yan YS, et al. Comparative efficacy of biological treatments for moderate-to-severe psoriasis: a network meta-analysis adjusting for cross-trial differences in reference arm response. Br J Dermatol 2015;172(2):504–12. https://doi.org/10.1111/bjd.13437.
Dias S, Welton NJ, Sutton AJ, Ades AE. NICE DSU Technical Support Document 2: A generalised linear modelling framework for pairwise and network meta-analysis of randomised controlled trials. London: National Institute for Health and Care Excellence (NICE); 2010. https://www.ncbi.nlm.nih.gov/books/NBK310366/.